Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis

MLA

Michael E. Weinblatt, et al. “Determinants of Serious Liver Disease among Patients Receiving Low-Dose Methotrexate for Rheumatoid Arthritis.” Arthritis & Rheumatism, vol. 36, Mar. 1993, pp. 329–35. EBSCOhost, https://doi.org/10.1002/art.1780360307.

APA

Michael E. Weinblatt, Alexander M. Walker, Randall G. Lee, Nancy A Dreyer, Joel M. Kremer, Keith G. Tolman, Graciela S. Alarcón, & Donnie Funch. (1993). Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis & Rheumatism, 36, 329–335. https://doi.org/10.1002/art.1780360307

Chicago

Michael E. Weinblatt, Alexander M. Walker, Randall G. Lee, Nancy A Dreyer, Joel M. Kremer, Keith G. Tolman, Graciela S. Alarcón, and Donnie Funch. 1993. “Determinants of Serious Liver Disease among Patients Receiving Low-Dose Methotrexate for Rheumatoid Arthritis.” Arthritis & Rheumatism 36 (March): 329–35. doi:10.1002/art.1780360307.